Sky Mirrors

The city of Melbourne.


Category#cityscapephotography
Camera ~ LensNikon D3400 DSLR ~ 18-55 mm
LocationAustralia

Prompt / Theme: Do you believe the acquisition of Steemit by TRON will be beneficial for the Steem ecosystem?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 200 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

Sunbakin’

Little lizard.



Category#animalphotography
Camera ~ LensNikon D3400 DSLR ~ 40 mm
LocationAustralia

Prompt / Theme: Do you feel people are fear mongering coronavirus or that it is under publicised?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 100 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

Unusual Options Activity In Met Life

MetLife, Inc. engages in
the insurance, annuities, employee benefits, and asset management businesses.  The company offers life, dental, group short-
and long-term disability, individual disability, accidental death and
dismemberment, vision, and accident and health coverages, etc. Serving
approximately 100 million customers, MetLife has operations in more than 40
countries and holds leading market positions in the United States, Japan, Latin
America, Asia, Europe and the Middle East.

MetLife was named Life
Insurance Company of the Year at the 2019 Middle East Insurance Industry Awards
(MIIA), organized by Middle East Insurance Review. As the fourth time recipient
of the award, MetLife was commended for its customer focus and recognized for
its efforts in enhancing the customer experience.

Last month, MetLife was
named one of America’s “Most Responsible Companies” by Newsweek
magazine. MetLife was the top-ranked insurance company on Newsweek’s inaugural
list, and number 19 of all 300 companies recognized.

Several months ago, MetLife got into the financial service business when it bought Bequest, Inc. Bequest helps customers draw up legally valid wills and estate planning documents online.

But an interesting move Metlife
made several weeks ago, was when it bought PetFirst Healthcare, a fast-growing
pet health insurance administrator.

The love affair with
pets, in particular cats and dogs goes back to the Egyptian times. Back in the
Egyptian times, dogs and cats were laid to rest in elaborate tombs decorated
with inscriptions, furnished with treasure and scented by incense. It’s
believed that dogs and cats improve human physical and mental health.

68% of households in
America have a pet. This is double the percentage of households that have
children. And pet owners will do practically anything or their cat or dog.

The pet insurance market is under-penetrated and fast-growing. The roughly 85 million families that own pets in the United States spend $18 billionii annually on veterinary care, yet, as of 2018, less than 2 percentiii of pets were insured. Following the acquisition, PetFirst will continue to market pet insurance through animal welfare societies and its direct-to-consumer channel. Beginning in the summer of 2020, MetLife will offer this pet insurance to employers through its leading group benefits distribution channel, reaching approximately 41 million employees and dependents across the U.S.

Katie Blakeley, CEO of PetFirst said, “For more than 15 years, we have proudly focused on developing products and services to meet the growing and evolving needs of pet parents across the U.S. During this time, we have seen pet insurance continue to gain importance as a valuable product for families. With MetLife’s tremendous reach and resources, we see a strong opportunity to help more pet parents get access to pet insurance and alleviate the potential financial burden of a sick or injured pet.”

Source

Metlife now offers a broader suite of products to serve their customers and their financial strengths is admired by investors.  So it only makes sense that yesterday, I noticed unusual options activity. The Smart Money bought over 50,000 March call options with strike price at $55.

What’s interesting about this trade is that price is approaching a weekly demand zone at $54.50. If I had to put my money on the zone or the Smart Money, my money would go to the Smart Money all the time. Stay tuned.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Did You Miss The Gold Move…Don’t Worry…

Lat month, gold fell below the psychological whole number of $1500 and was 5% down from the 6-year-peak reached in September due to profit taking and investors wanting to take on more risks. But the charts told you where the sellers were going to step before hand and for that matter where the buyers were going to step in before hand as well based on the monthly supply and demand zones.

Gold never did hit the monthly demand, missed the zone by $5 and has since rallied. The US air strike in Baghdad ordered by President Donald Trump that killed Qassem Soleimani, has been the catalyst not only for gold, but all the other precious metals as well.

But if you missed the rally in gold, don’t worry, according to one article I read this morning, gold is due for a pull back.

Gold is almost guaranteed to record losses in the next two weeks, if history is any guide.

The 14-day Relative Strength Index for the yellow metal soared to 86 on Monday, well above the level of 70 that typically suggests securities are overbought. Previously, there have been only three times since 2000 when the RSI rose above 85, and in each instance bullion fell over the next 10 trading days. The loss averaged 1% compared with a gain of 7% over the previous 10 session.

To be sure, in all three occasions — October 2010, February 2016 and June 2019 — gold eventually resumed its rally. But the momentum had slowed. Gold performs best when interest rates fall and the dollar weakens. Without a further escalation of Middle East tensions, the bulk of the moves in rates and the dollar may be over for now. And the same is probably true for the bounce in gold, at least in the short term.

Source

From my perspective, there is only one reason why gold will pull back and that’s because price are in a monthly supply zone.

Supply and demand zones can often indicate institutional buying and selling. The big market participants cannot just enter one trade at once, they need to slowly build their position over time. And often their positions are so large that they will absorb most unfilled orders before price make big and explosive moves on price charts.

Take for instance the daily supply at $1560. Price entered the daily supply and two days later shot down, but when price returned to the zone several months later, well there weren’t any unfilled orders remaining at that level.

On Sunday, price gapped up into a monthly supply zone and has sense formed a shooting star candle, which is is a bearish and signals a reversal.

But again, the shooting star only formed because the Smart Money was able to fill, unfilled orders at that level. Ideally, what I would like to see is price breach the monthly supply at $1600, pull back, then move higher to the monthly supply at $1700. But this may or may not happen in that order. So if you missed the rally and want to get long, two level to consider are the daily demand at $1520, but I think the better level to go long is at $1475.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Tesla Continues To Beat The Odds

Earlier in 2019, a former hedge fund manager, Whitney Tilson said Tesla will be below $100 by the end of 2019. At the time, Tesla was trading at $295, but Whitney felt Musk has no more rabbits to pull out of his hat and therefore it was all downhill from there. Whitney also felt for the first time, the number of investors losing faith in Musk is starting to exceed the number of investors. Two months, Tesla announced that was looking to raise almost $3 billion in debt and equity, with Elon buying $25 million in stock as good faith, upping Elon’s stake in the company to 20%.

One of the more famous short sellers is Jim Chanos. Jim Chanos is an American investment manager and currently serves as president and founder of Kynikos Associates, a New York City registered investment advisor who is focused on short selling.

Jim is the same person that made headlines when he said Grubhub was a short due to Grubhub’s inability to make any money on each order. Weeks later, Grubhub announced dismal earnings and the stock tanked.

Regarding Tesla, there were rumors that Jim Chanos covered his shorts on Tesla, but it was in fact just a rumor. What concerns Jim is that Tesla’s valuation within a capital intensive business, making cars. Jim thinks the Model S is a great car, but the competition is knocking on the door. In addition, he feels demand for the Model 3 in North America has peaked. And lastly, Jim feels Elon’s behavior is “promotional,” meaning he promises the world, but under delivers.

Short sellers have long targeted Tesla shares and currently have almost a $10 billion bet against the Tesla according to data from the financial analytics firm S3 Partners. The 28 million shares shorted amount to 21% of total shares outstanding, according to S3.

But there is one bull, who has been bullish on Tesla for many years.

Catherine’s firm focuses disruptive technologies and thinks electric there will be millions and millions of cars on the road faster than people realize. She believe Tesla isn’t a car company, but a technology company, Tesla is one of her fund’s largest holdings. In February of 2018 she went on CNBC and said she believes Tesla could hit $4000 and that her bear case was $600.  In recent weeks, she went back on CNBC and reiterated her targets for Tesla.

Tesla Inc (NASDAQ: TSLA) shares gained 3% on Friday after the company reported better-than-expected fourth-quarter delivery numbers. The electric vehicle stock is now up 99% in just the past six months, but Tesla short sellers are seemingly still not convinced the rally will last.

Tesla reported 112,000 vehicle deliveries in the fourth quarter, beating consensus analyst estimates of 106,000 vehicles. For the full year, Tesla delivered 367,500 vehicles in 2019, up 50% from 2018. The 367,500 deliveries was on the low end of the company’s 2019 guidance range of between 360,000 and 400,000 deliveries.

On Friday, S3 Partners analyst Ihor Dusaniwsky said there are still 27.64 million shares of Tesla held short, a position worth about $11.89 billion. That short interest represents about 20.6% of Tesla’s float.

Source

If the current price action doesn’t scare the Shorts, Tesla delivered the first China-made Model 3 one week ago. During their fourth quarter earnings call, Tesla announced that factory has already demonstrated production run-rate of 3,000 units per week and they have the necessary means to get to 150,000 units / year or 40% of Tesla’s current annualized global deliveries.

The fact that price broke out last month, the chart suggest the Shorts are due in for more pain ahead.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Colourful

Interesting little flower.



Category#naturephotography
Camera ~ LensNikon D3400 DSLR ~ 40 mm
LocationAustralia

Prompt / Theme: Any fun over Christmas? A wild party or a peaceful holiday?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 100 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

Worst Stocks Of This Decade

Yesterday, I wrote a post about Facebook. Mark Zuckerberg was onto something in his dorm room at Harvard before he dropped out to focus on Facebook. The company went public in 2012, dropped 50%, switch their focus to mobile and the stock price hasn’t looked back. If one invested $1000 in Facebook during the IPO, you would be up over $5000 or a 500% ROI.

But all that is glitter is not gold. “All that glitters is not gold” is an aphorism stating that not everything that looks precious or true turns out to be so. This can be applied to just about any experience in life. It could also be applied to the stock market.

So the worst stocks of the decade go to:

  1. Apache. Ten-year performance: -78%
  2. Freeport-McMoRan. Ten-year performance: -68%
  3. Devon Energy. Ten-year performance: -66%
  4. The Mosaic Company. Ten-year performance: -65%
  5. CenturyLink. Ten-year performance: -63%
  6. Kraft Heinz. Ten-year performance: -56%
  7. Perrigo. Ten-year performance: -54%
  8. Under Armour. Ten-year performance: -54%
  9. Occidental Petroleum. Ten-year performance: – 51%
  10. Schlumberger. Ten-year performance: -31%

Now if you know these companies, 40% of the companies on the list were in the oil and gas industry. The oil and gas sector (aqua block) was the worst performing sector this year.

Source

  1. Technology: 48%
  2. Communication: 32%
  3. S&P 500: 31%
  4. Financials: 31%
  5. Industrials: 28%
  6. Staples: 27%
  7. Discretionary: 27%
  8. Real Estate: 26%
  9. Materials: 22%
  10. Health Care: 20%
  11. Energy: 10%

And Energy compared to the SPY has under-performed going back for five years.

Now the Dow Dogs involves buying the ten stocks with the highest yields among the thirty in the Dow Jones Industrial Average at the end of each year then holding them until the end of the next year. I don’t know what they call the worst stocks of the decade and potentially hold them for 10 years. But that’s what the Smart Money is doing.

Over the last several weeks, I have been posting about the bullishness going on in the oil and gas industry by way of the Smart Money buying up assets. In particular Sam Zell, Steven Cohen, Ken Griffin and Ray Dalio, all billionaires are buying distressed oil assets in the US.

I have to start looking at this sector as well. Besides that’s the premise of my trading edge, follow the Smart Money. I’m feeling the trade that Ray Dalio bought more of. Ray didn’t become wealthy by buying asset at high prices. Recently Ray’s hedge fund bought an additional 1,177,026 shares to the fund, increasing his stake to over 2.5 million shares.

EQT Corporation operates as a natural gas production company in the United States. It produces natural gas, natural gas liquids (NGLs), and crude oil. EQT is the largest natural gas producer in the U.S. with its asset base located in the heart of the Appalachian Basin with a focus in Pennsylvania, Ohio and West Virginia.

I would like to see price close above $13 as confirmation that price will continue to rise.

I thought EQT Corp was a Master Limited Partnership, but they aren’t, so don’t they pay much dividends. Thus, I’m not interested in own the stock, but look what I just found. The Smart Money already bought LEAP options going out to January of 2021. So best believe I will be buying some options on Monday.

Look at that, went from taking about the worst stocks of the decade to wanting to get in the worst sector of decade on Money.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

West Coast

Life is sometimes a turmoil.



Category#naturephotography
Camera ~ LensNikon D3400 DSLR ~ 18-55 mm
LocationAustralia

Prompt / Theme: Got your Christmas organised? What’s your favourite present you’ve bought?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 100 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

So Was The FDA Approval Already Priced Into Amarin’s Stock???

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.

The company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

About a year ago, Amarin published results from a study that show patients who took Vascepa in addition to a statin experienced a 25% reduction in risk of a heart attack, stroke or other serious cardiac event, compared with patients who took a placebo instead of Vascepa. Thus, Amarin wants to get Vascepa approved for other use, which could potentially generate up $2 billion in sales.

Assuming avg. P/E of 15-24 for companies in the pharmaceutical space and Amarin’s market cap, if Vascepa sales can reach $2 billion in the years to come, the stock would be worth approx $125.

Yesterday, the FDA approved the label extension for Vascepa, but the stock price seem bored by the announcement.

Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the label extension of the company’s fish oil drug, Vascepa.

That’s good news for Amarin, but less good news for long-term investors. You see, according to the principle of “buy the rumor, sell the news,” the major catalyst for Amarin stock to rise has now been removed, and traders who were awaiting the FDA approval have now reaped all the gains they’re going to get from that particular catalyst. Hence, they’re selling the stock today.

One of these sellers, Stifel’s Derek Archila, wrote in a research note to clients, “We are taking profits post approval and heading to the sidelines.” Indeed, the analyst downgraded AMRN from Buy to Hold, while slightly raising the price target to $28 (from $26), which still implies about 20% upside from current levels.

Source

Many think Amarin’s stock price at $22.88 is a steal and think the stock is worth $50 in the future.    According to FiercePharma, market chatter is now valuing the company at a $20 billion market cap, or $55 a share, if the company is acquired.  So is the stock still worth a buy?

NOTE: since Sept of 2018, the stock has increased from $3 to a little over $20 in 14 months.

To answer the question if the stock is still worth a buy or not, you have to know your time horizon.  Once you know your time horizon, than you can select your target price.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Tandem Diabetes Is Worth Keeping An Eye On

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body’s systems, especially the nerves and blood vessels

More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released today by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans – 9.4 percent of the U.S. population –have diabetes. Another 84.1 million have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years.

Source

The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump’s software

Tandem’s t:slim X2 is the smallest durable insulin pump on the market at present and is the only pump in the US market that offers remote software updates. Also, the insulin pump integrates with Dexcom’s G6 continuous glucose monitoring (CGM) system, is the first automated insulin-delivery system approved for use in children as young as six years old.

Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days.These disposable products are great because they produce reoccurring revenue (think of the disposable razors for the Gillette razor blade…which I hate buying because I know they are overpriced).

Since 2012,Tandem has sold over 72,000 pumps in the US, but 63,000 pumps have been sold in the last four years. In addition, Tandem is also going international to capture opportunities after Johnson & Johnson’s exit from the insulin pump market. This is good because Tandem has penetrated less than 1% of the total addressable diabetes market worldwide.

In recent weeks, Tandem attained Health Canada approval for the t:slim X2 insulin pump with Basal-IQ technology. This approval is expected to accelerate Tandem Diabetes’ global pump shipments and expand its customer base.

But just the other day, Tandem got better news.

Tandem Diabetes (TNDM) nabbed Food and Drug Administration clearance for a new diabetes management system Friday — prodding TNDM stock to pop midday.

The FDA cleared a diabetes management system dubbed Control-IQ to work with Tandem’s insulin pump, dubbed t:slim X2. The closed loop system works with Dexcom’s (DXCM) continuous glucose monitor. The devices automatically adjust insulin to prevent high and low blood sugar.

With the clearance, the FDA also created a new category for interoperable medical devices, known as an automated insulin dosing system. This diabetes management system has the potential to rival devices from Medtronic (MDT).

Source

The potential to take on Medtronic is a big deal as Medtronic is the 800 lb gorilla in the room. One should keep Tandem on their radar screen and the levels to pay attention to are the weekly zones near $80 and near $45.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.